NCT00562068View on ClinicalTrials.gov

Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma

PHASE1UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

May 31, 2009

Conditions
LymphomaSmall Intestine Cancer
Interventions
BIOLOGICAL

alemtuzumab

DRUG

cyclophosphamide

DRUG

doxorubicin hydrochloride

DRUG

prednisolone

DRUG

vincristine sulfate

GENETIC

polymerase chain reaction

OTHER

flow cytometry

OTHER

laboratory biomarker analysis

OTHER

pharmacological study

Trial Locations (5)

LS1 3EX

RECRUITING

Leeds General Infirmary, Leeds

SE5 9RS

RECRUITING

King's College Hospital, London

SW3 6JJ

RECRUITING

Royal Marsden - London, London

M20 4BX

RECRUITING

Christie Hospital, Manchester

TQ2 7AA

RECRUITING

Torbay Hospital, Torbay Devon

Sponsors

Lead Sponsor

Cancer Research UK
All Listed Sponsors
lead

Cancer Research UK

OTHER